Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma | SpringerLink

Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma | SpringerLink

Investigational New Drugs

pp 1–11| Cite as

Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma

• Authors
• Authors and affiliations

• Yanrong Li
• Kai Wang
• Na Song
• Kezuo Hou
• Xiaofang Che
• Yang Zhou
• Yunpeng Liu
• Jingdong Zhang